Abstract 682TiP
Background
CD147 is an immunoglobulin (Ig) superfamily membrane protein involved in key hallmarks of cancer such as cell survival, proliferation, and metastasis; it is highly expressed across a range of cancers. High CD147 expression in tumor tissue is associated with poor prognosis in multiple solid tumors, making CD147 an attractive target for novel cancer therapeutics. DS-1471, a humanized IgG4 monoclonal antibody targeting CD147, has shown preclinical antitumor activity by inhibiting complex formation between CD147 and diverse binding partners and inducing cancer cell apoptosis via upregulating a stress response. The toxicity profile and antitumor activity of DS-1471 in preclinical studies warrant clinical investigation. DS-1471 is currently being evaluated in a Phase 1 trial.
Trial design
DS-1471-079 (NCT06074705) is a Phase 1, first-in-human, open-label, multicenter, 2-part dose-escalation and -expansion study in adult patients with locally advanced or metastatic solid tumors who are unable to tolerate, whose tumors are refractory to, or who lack available standard treatment (N≈80). The study is currently recruiting. Patients must have ≥1 measurable lesion per Response Evaluation Criteria in Solid Tumors v1.1, have an Eastern Cooperative Oncology Group performance status of 0 or 1, and consent to baseline (mandatory) and on-treatment (if not contraindicated) biopsy. During dose escalation, patients will receive DS-1471 intravenously (IV) on Day 1 of each 28-day cycle. The primary objective of dose escalation is to evaluate the safety and tolerability of DS-1471 IV and determine the maximum tolerated dose and/or recommended dose for expansion (RDE). The dose-expansion part will comprise tumor-specific cohorts, determined based on dose escalation and preclinical data, in which patients receive DS-1471 IV at the RDE. The primary objective of dose expansion is to evaluate the safety of DS-1471 IV at the RDE. Safety measures for primary outcomes in this study include dose-limiting toxicities and treatment-emergent adverse events. Secondary outcome measures for both parts include best overall response, time to response, duration of response, progression-free survival, and overall survival.
Clinical trial identification
NCT06074705.
Editorial acknowledgement
Medical writing support was provided by Alexandra Mascaro, PhD, of Boldscience®, Inc.
Legal entity responsible for the study
Daiichi Sankyo.
Funding
Daiichi Sankyo.
Disclosure
S. Koganemaru: Financial Interests, Institutional, Principal Investigator: Amgen, Bristol Myers Squibb, Daiichi Sankyo, AbbVie, MSD, Incyte, Eisai Inc. N. Yoshizuka: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks/Shares: Daiichi Sankyo. S. Mizuno, S. Hirai: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. N. Yamamoto: Financial Interests, Personal, Advisory Role: Eisai, Takeda, Boehringer Ingelheim, Cmic, Chugai, Merck, Healios; Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo, Eisai; Financial Interests, Institutional, Principal Investigator: Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, Ono, Janssen Pharma, MSD, Merck, GSK, Sumitomo Pharma, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, Toray, Kaken, AstraZeneca, Cmic, InventisBio, Rakuten Medical.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01